Johnson & Johnson (Brazil)

Recent papers from Johnson & Johnson (Brazil)

1. Comparing operational definitions of screening-based cognitive impairment in the Tohoku Medical Megabank cohort: Focus on digital engagementJournal of Alzheimer s Disease · 2026
2. The 20 th EFMC Short Course on Medicinal Chemistry Dedicated to Atypical Approaches Focusing on Protein TargetsChemMedChem · 2026
3. Disease characteristics, outcomes, and poor prognostic factors of perianal fistula in Korean patients with Crohn’s disease: a multicenter, retrospective observational studyIntestinal Research · 2026
4. A phase 1, first-in-human study of safimaltib, a MALT1 inhibitor, in B-lymphocytic malignanciesBlood Cancer Discovery · 2026
5. Dual targeting of BCMA and GPRC5D with the trispecific antibody ramantamig addresses antigenic heterogeneity in myelomaHemaSphere · 2026
6. Mortality and Hospitalization in Autoimmune Hemolytic Anemia: A 14-Year Population-Based Study in Brazil, 2010-2023Hematology Transfusion and Cell Therapy · 2026
7. Real-World Treatment Patterns and Clinical Outcomes of Patients With Primary Autoimmune Hemolytic Anemia in Brazil: A Claims Database StudyHematology Transfusion and Cell Therapy · 2026
8. Treatment patterns, intensive treatment, and hospitalization-related burden of juvenile generalized myasthenia gravis in Japan: a retrospective cohort study using a hospital-based claims databaseFrontiers in Neurology · 2026
9. Amivantamab plus pembrolizumab in previously untreated recurrent/metastatic head and neck squamous cell cancer: Results from the phase 1b/2 OrigAMI-4 studyClinical Cancer Research · 2026
10. Data-independent acquisition (DIA) approach for comprehensive ubiquitinome profiling in targeted protein degradationScientific Reports · 2026
11. Real-world treatment patterns and disease burden in generalized myasthenia gravis patients receiving non-steroidal immunosuppressants within the Brazilian public health system: a claims database studyBMC Neurology · 2026
12. Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experienceHematology · 2026
13. Nipocalimab Phase 3 Dose Selection for Severe Hemolytic Disease of the Fetus and NewbornThe Journal of Clinical Pharmacology · 2026
14. Targeted degradation of alpha-synuclein impedes PFF-induced aggregationnpj Parkinson s Disease · 2026
15. Japanese subgroup analysis of AQUILA trial: daratumumab vs active monitoring in high-risk smoldering multiple myelomaJapanese Journal of Clinical Oncology · 2026
16. High‐Throughput Experimentation‐Assisted Optimization of the Suzuki–Miyaura Coupling Using Palladium– N ‐Heterocyclic Carbene PrecatalystsAdvanced Synthesis & Catalysis · 2026
17. Viral Dynamic Model‐Informed Dose Selection of Mosnodenvir Prophylaxis against DENV ‐3 in a Controlled Human Infection ModelClinical Pharmacology & Therapeutics · 2026
18. Inflammatory Mechanisms in the AML Bone Marrow Niche: From Pathogenesis to TherapyCytokine & Growth Factor Reviews · 2026
19. Molecular Epidemiology and Drug Resistance of Extraintestinal Pathogenic Escherichia coli Bloodstream Isolates From Adults Worldwide (2011–2023)Clinical Infectious Diseases · 2026
20. Quantum Pharmacophore-Based Virtual Screening Enables Prospective Discovery of Chemotype-Diverse Dengue NS5 InhibitorsJournal of Chemical Information and Modeling · 2026